There are currently 548 clinical trials in Charlotte, North Carolina looking for participants to engage in research studies. Trials are conducted at various facilities, including Carolinas Medical Center, Carolinas Medical Center/Levine Cancer Institute, Novant Health Presbyterain Medical Center and Levine Cancer Institute. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Oxbryta® Product Registry An Observational Study Designed to Evaluate the Effect of Oxbryta in Individuals With SCD
Recruiting
This registry is an observational study designed to evaluate the effect of Oxbryta in individuals with SCD in a real-world setting.
Gender:
All
Ages:
4 years and above
Trial Updated:
04/10/2024
Locations: Levine Cancer Institute, Charlotte, North Carolina
Conditions: Sickle Cell Disease
Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies
Recruiting
This clinical trial keeps track of and collects follow-up information from patients who are currently enrolled on or have participated in a Children's Oncology Group study. Developing a way to keep track of patients who have participated in Children's Oncology Group studies may allow doctors learn more about the long-term effects of cancer treatment and help them reduce problems related to treatment and improve patient quality of life.
Gender:
All
Ages:
All
Trial Updated:
04/10/2024
Locations: Carolinas Medical Center/Levine Cancer Institute, Charlotte, North Carolina +1 locations
Conditions: Hematopoietic Cell Transplantation Recipient, Leukemia, Solid Tumor
Sponsor-Initiated OCS Liver Perfusion (OLP-II) Registry
Recruiting
OLP-II Registry is a sponsor-initiated, multi-center, observational, post-approval registry.
Gender:
All
Ages:
All
Trial Updated:
04/10/2024
Locations: Carolinas Medical Center/Atrium Health, Charlotte, North Carolina
Conditions: Liver Transplant
Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Recruiting
This randomized phase III trial studies how well imatinib mesylate works in combination with two different chemotherapy regimens in treating patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (ALL). Imatinib mesylate has been shown to improve outcomes in children and adolescents with Philadelphia chromosome positive (Ph+) ALL when given with strong chemotherapy, but the combination has many side effects. This trial is testing whether a different chemother... Read More
Gender:
All
Ages:
Between 1 year and 21 years
Trial Updated:
04/10/2024
Locations: Carolinas Medical Center/Levine Cancer Institute, Charlotte, North Carolina +1 locations
Conditions: Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, Mixed Phenotype Acute Leukemia, T Acute Lymphoblastic Leukemia
A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive HCM)
Recruiting
The purpose of this study is to evaluate the safety of mavacamten in patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM) treated in the real-world setting. The registry study also provide a real-world understanding of the current obstructive HCM patient population, treatment patterns, and clinical relevant outcomes for patients with symptomatic obstructive HCM in the US.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/09/2024
Locations: Focus Clinical Research, Charlotte, North Carolina
Conditions: Obstructive Hypertrophic Cardiomyopathy
Post Approval Study (PAS) of the OPTIMIZER Smart and CCM Therapy
Recruiting
The OPTIMIZER Smart Post-Approval Study is a prospective, multi-center, non-randomized, single arm open label study of 620 subjects receiving an OPTIMIZER implant as standard of care. Patients to be included will have NYHA functional class III symptoms and a left ventricular ejection fraction of 25-45%
Gender:
All
Ages:
18 years and above
Trial Updated:
04/09/2024
Locations: Atrium Health, Charlotte, North Carolina
Conditions: Heart Failure
PEACH TRIAL- Precision Medicine and Adoptive Cellular Therapy
Recruiting
A Phase I open-label, multicenter study, to evaluate the safety, feasibility, and maximum tolerated dose (MTD) of treating children with newly diagnosed DIPG or recurrent neuroblastoma with molecular targeted therapy in combination with adoptive cell therapy (Total tumor mRNA-pulsed autologous Dendritic Cells (DCs) (TTRNA-DCs), Tumor-specific ex vivo expanded autologous lymphocyte transfer (TTRNA-xALT) and Autologous G-CSF mobilized Hematopoietic Stem Cells (HSCs)).
Gender:
All
Ages:
Between 1 year and 30 years
Trial Updated:
04/09/2024
Locations: Levine Children's Hospital, Charlotte, North Carolina
Conditions: Neuroblastoma, Diffuse Intrinsic Pontine Glioma
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
Recruiting
The phase III trial compares the effect of pembrolizumab to observation for the treatment of patients with early-stage triple-negative breast cancer who achieved a pathologic complete response after preoperative chemotherapy in combination with pembrolizumab. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial may help researchers determine if observa... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/08/2024
Locations: Novant Health Presbyterian Medical Center, Charlotte, North Carolina
Conditions: Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Early Stage Triple-Negative Breast Carcinoma
AMPLATZER PFO Occluder Post Approval Study
Recruiting
The purpose of this single arm, multi-center study is to confirm the safety and effectiveness of the AMPLATZER™ PFO Occluder in the post Approval Setting.
Gender:
All
Ages:
Between 18 years and 60 years
Trial Updated:
04/08/2024
Locations: Novant Health Heart and Vascular Research, Charlotte, North Carolina
Conditions: Stroke, Patent Foramen Ovale
A Randomized, Double-Blind, Placebo Controlled, Multicenter, Efficacy and Safety Trial of Single Cycle Tetrodotoxin in the Treatment of Chemotherapy Induced Neuropathic Pain
Recruiting
To be eligible for the trial, subjects must have ongoing moderate to severe neuropathic pain related to a prior course of platinum and/or taxane chemotherapy and have no clinical evidence of actively progressive disease. The trial period will comprise a Screening period (up to 35 Days), randomization and a 4-day treatment period, followed by a 12-week follow up period (12 weeks total after initial treatment), and an End-of-Trial/Follow-up visit which will occur at Week 13. This is a study to re... Read More
Gender:
All
Ages:
21 years and above
Trial Updated:
04/05/2024
Locations: Oncology Specialists of Charlotte, Charlotte, North Carolina
Conditions: Chemotherapy-induced Neuropathic Pain, Chemotherapy-induced Peripheral Neuropathy
Neuropsychological and Behavioral Testing in Younger Patients With Cancer
Recruiting
This research trial studies neuropsychological (learning, remembering or thinking) and behavioral outcomes in children and adolescents with cancer by collecting information over time from a series of tests.
Gender:
All
Ages:
1 month and above
Trial Updated:
04/05/2024
Locations: Carolinas Medical Center/Levine Cancer Institute, Charlotte, North Carolina +1 locations
Conditions: Childhood Malignant Neoplasm
Study to Assess the Efficacy and Safety of MT-3921 in Subjects With Acute Traumatic Cervical Spinal Cord Injury
Recruiting
The purpose of this study is to compare the efficacy and safety of intravenous (IV) infusions of MT-3921 to placebo in subjects with acute traumatic cervical spinal cord injury. Subjects meeting eligibility criteria will enter the 6-month double-blind period. Subjects will be randomized in a 2:1 ratio to receive MT-3921 or placebo in a double blind manner.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
04/05/2024
Locations: Atrium Health Rehabilitation & Therapy, Charlotte, North Carolina
Conditions: Spinal Cord Injury